Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants (ATCCTCP-1)

• ClinicalTrials.gov Identifier: NCT01511939
• Recruitment Status: Completed
• First Posted: January 19, 2012
• Results First Posted: June 26, 2014
• Last Update Posted: June 26, 2014
• Sponsor: Nathan Wei, MD, FACP, FACR:
• Collaborators: Medtronic - MITG; Arthritis Treatment Center, Maryland
• Information provided by (Responsible Party): Nathan Wei, MD, FACP, FACR:, Arthritis Treatment Center, Maryland

Study Description

Brief Summary:

The purpose of this study is to see if using a topical nonsteroidal antiinflammatory drug (Pennsaid) to treat osteoarthritis knee pain will affect coagulation values in patients who are also taking anticoagulant or antithrombotic medications.

Condition or disease	Intervention/treatment	Phase
Osteoarthritis of the Knee; Coagulopathy	Drug: Pennsaid	Phase 3

Detailed Description:

Open-label active treatment Phase III study of Pennsaid (diclofenac sodium 1.5% topical solution) to determine the effects on coagulation parameters in patients who are equal to or greater than 55 years of age with moderate to severe osteoarthritis knee pain and who are also taking warfarin, dabigatran, or aspirin and/or clopidogrel.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 22 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Single Center, Open-label Study of Effect of PENNSAID (Diclofenac Sodium Solution Topical) on Coagulation Parameters (PT, PTT, INR and Platelet Function) in Patients With Moderate to Severe Osteoarthritis Pain of the Knee Taking Anticoagulant Medication
• Study Start Date: February 2012
• Actual Primary Completion Date: May 2013
• Actual Study Completion Date: May 2013

Arms and Interventions

Arm	Intervention/treatment
Pennsaid, warfarin; Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months	Drug: Pennsaid; Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.; Other Names: Pennsaid 1.5%; Diclofenac sodium 1.5% topical solution; Topical nonsteroidal antiinflammatory drug; Topical NSAID
Pennsaid, dabigatran; Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months	Drug: Pennsaid; Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.; Other Names: Pennsaid 1.5%; Diclofenac sodium 1.5% topical solution; Topical nonsteroidal antiinflammatory drug; Topical NSAID
Pennsaid, aspirin and/or clopidogrel; Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months	Drug: Pennsaid; Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.; Other Names: Pennsaid 1.5%; Diclofenac sodium 1.5% topical solution; Topical nonsteroidal antiinflammatory drug; Topical NSAID

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline to Week 4 in Laboratory Results of Prothrombin Time (PT) [ Time Frame: Baseline to week 4 ]
   PT will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
2. Change From Baseline to Week 4 in Laboratory Results of International Normalized Ratio (INR) [ Time Frame: Baseline to Week 4 ]
   INR will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
3. Change From Baseline to Week 4 in Laboratory Results of Partial Thromboplastin Time (PTT) [ Time Frame: Baseline to Week 4 ]
   PTT will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
4. Change From Baseline to Week 4 in Laboratory Results of Platelet Aggregation [ Time Frame: Baseline to Week 4 ]
   Platelet Aggregation will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.

Eligibility Criteria

• Ages Eligible for Study: 55 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female adults > than or equal to 55
• Ambulatory subjects with moderate to severe osteoarthritis (OA) of the knee with symptoms and knee pain for at least 3 months and pain on the majority of days in the last 30 days.
• Subjects with bilateral knee OA, the more symptomatic knee is the index knee and PENNSAID can be applied on both knees if both are affected.
• Radiographic evidence of Kellgren-Lawrence Grade 2-4 within the past 2 years.
• Currently on a stable dose of anticoagulant therapy (warfarin, dabigatran, aspirin or clopidogrel) for the past 2 months and expected to remain on current dose for the six week duration of the study.
• If currently taking oral nonsteroidal antiinflammatory drug (NSAID) and/or acetaminophen for OA knee pain, must be taking it for at least an average of 25 days per month.
• Those currently taking oral NSAID must be willing to perform a 7 day washout to be eligible to be enrolled into the study.
• A pain score of > than 40mm on the Patient Pain Visual Analog Scale (VAS) (100 mm scale) at screening and baseline visit.
• Able to comply with the study and give informed consent prior to performance of any study procedures.
• Able to read, write and understand English.

Exclusion Criteria:

• Unwilling to abstain from oral NSAIDs and/or other analgesic medication except for acetaminophen as rescue medication. Subjects taking low dose aspirin for cardiovascular health may remain on their stable dose throughout the study.
• Unwilling to abstain from taking < than or equal to 1500mg of acetaminophen a day for rescue medication purposes during the 6 week course of the trial.
• Using a handicap assistance device i.e. cane, walker > than or equal to 50% of the time.
• Undergoing new physical therapy or participating in a weight loss or exercise program that has not been stable for at least 3 months prior to screening and won't remain stable during participation in study.
• History or diagnosis of an inflammatory arthritis i.e. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis.
• Known or clinically suspected infection and human immunodeficiency virus (HIV), or hepatitis C or B viruses.
• History of abnormal laboratory results > that or equal to 2.5 x upper limit of normal (ULN) indicative of any significant medical disease which in the opinion of the investigator, would preclude the subjects participation in the study.
• Any of the following abnormal laboratory results during screening:
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > than or equal to 2.5 x ULN
• Hemoglobin < than 11.5 g/dL (female) or < 13.2 g/dL (male)
• White blood cell count (WBC) < than 3500 cells/mm3
• Lymphocyte count < than or equal to 1000 cels/mm3
• Serum creatinine > than or equal 1.5 x ULN
• Platelet count below the central laboratory lower limit of normal (LLN)
• Coagulation tests (Prothrombin Time (PT), Partial Thromboplastin Time (PTT), International Normalized Ratio (INR), Platelet Aggregation) requiring an alteration in anticoagulant dosage.
• Skin breakdown or rash at knee where topical PENNSAID is to be applied.
• Other serious uncontrolled non-malignant, significant, acute or chronic medical or psychiatric illness that, in judgment of investigator, could compromise subject safety, limit subject's ability to complete study and/or compromise the objectives of study.
• History of malignancy in the past 5 years with exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.
• History of drug or alcohol dependence or abuse in the past 3 years.

Contacts and Locations

Locations

United States, Maryland

Arthritis Treatment Center

Frederick, Maryland, United States, 21702

Sponsors and Collaborators

Nathan Wei, MD, FACP, FACR:

Medtronic - MITG

Arthritis Treatment Center, Maryland

Investigators

• Principal Investigator: Nathan Wei, MD,FACP,FACR; Arthritis Treatment Center, Frederick, Maryland, United States, 21702

More Information

• Responsible Party: Nathan Wei, MD, FACP, FACR:, Nathan Wei, MD, FACP, FACR, Arthritis Treatment Center, Maryland
• ClinicalTrials.gov Identifier: NCT01511939
• Other Study ID Numbers: ATCCTCP-1
• First Posted: January 19, 2012
• Results First Posted: June 26, 2014
• Last Update Posted: June 26, 2014
• Last Verified: June 2014

Keywords provided by Nathan Wei, MD, FACP, FACR:, Arthritis Treatment Center, Maryland:

Knee pain; Anticoagulant; Warfarin; Dabigatran; Clopidogrel; Aspirin; Topical NSAID; Osteoarthritis

Additional relevant MeSH terms:

Osteoarthritis; Osteoarthritis, Knee; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Diclofenac; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Antirheumatic Agents; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action